
-
Trump urges 60-day Gaza ceasefire deal ahead of Netanyahu visit
-
Partial verdict in Combs trial, jury will keep deliberating
-
Djokovic thanks 'miracle pills' after Wimbledon win
-
US college bans transgender athletes following swimming furor
-
Global stocks mixed as markets track US trade deal prospects
-
Djokovic up and running at Wimbledon in bid for Grand Slam history
-
Jury reaches partial verdict in Sean "Diddy" Combs trial
-
Giroud signs one-year deal with Ligue 1 club Lille
-
Gauff vows to make changes after shock Wimbledon exit
-
Gonzalo heads Real Madrid past Juventus and into Club World Cup quarters
-
Gauff crashes out of Wimbledon on day of shocks
-
Big automakers report US sales jump on pre-tariff consumer surge
-
'Alone' Zverev considers therapy after shock Wimbledon exit
-
Second seed Coco Gauff knocked out of Wimbledon
-
Switzerland comes to the aid of Red Cross museum
-
'That's life': No regrets for former champion Kvitova after Wimbledon farewell
-
AI videos push Combs trial misinformation, researchers say
-
UK govt guts key welfare reforms to win vote after internal rebellion
-
Polish supreme court ratifies nationalist's presidential vote win
-
Macron, Putin discuss Iran, Ukraine in first talks since 2022
-
French league launches own channel to broadcast Ligue 1
-
Man City left to reflect on Club World Cup exit as tournament opens up
-
Shock study: Mild electric stimulation boosts math ability
-
Europe swelters as surprise early summer heatwave spreads
-
Third seed Zverev stunned at Wimbledon
-
Israel expands Gaza campaign ahead of Netanyahu's US visit
-
Gaza mourns those killed in Israeli strike on seafront cafe
-
Rubio hails end of USAID as Bush, Obama deplore cost in lives
-
Berlusconi family sell Monza football club to US investment fund
-
UN aid meeting seeks end to Global South debt crisis
-
Trump ramps up Musk feud with deportation threat
-
French paparazzi boss handed 18-month suspended sentence for blackmail
-
Gilgeous-Alexander agrees record $285 mln extension: reports
-
Tearful former champion Kvitova loses on Wimbledon farewell
-
IMF urges Swiss to strengthen bank resilience
-
Sri Lanka eye top-three spot in ODI rankings
-
Trump hails new 'Alligator Alcatraz' migrant detention center
-
US Senate approves divisive Trump spending bill
-
Krejcikova toughs it out in Wimbledon opener, Sinner cruises
-
UK govt braces for crunch welfare reforms vote amid major rebellion
-
Shifting to Asia, Rubio meets Quad and talks minerals
-
Stocks diverge while tracking US trade deal prospects
-
Bruce Lee Club closes archive doors citing operating costs
-
Trump ramps up Musk feud with deportation, DOGE threats
-
BTS announces comeback for spring 2026
-
Beating England without Bumrah 'not impossible' for India captain Gill
-
Krejcikova battles back against rising star Eala to win Wimbledon opener
-
US Republicans close in on make-or-break Trump mega-bill vote
-
Arsenal sign goalkeeper Kepa from Chelsea
-
Olympic champion Zheng knocked out of Wimbledon

Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
A.Jones--AMWN